Cancer Chemotherapy and Pharmacology

, Volume 70, Issue 3, pp 381–389 | Cite as

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer

  • Jae-Sung Kim
  • Joo Han Lim
  • Jee Hyun Kim
  • Seock-Ah Im
  • Eui Kyu Chie
  • Jin-Hyeok Hwang
  • Tae-You Kim
  • Yung-Jue Bang
  • Sung Whan Ha
  • Yong Bum Yoon
Original Article

Abstract

Purpose

5-FU-based concurrent chemoradiotherapy (CRT) has been the mainstay of treatment for locally advanced pancreatic cancer (LAPC) for the past decades, but the prognosis remains dismal.

Methods

Patients with pathologically confirmed LAPC of the pancreas, an ECOG PS of 0–2 and no prior chemo- or radiotherapy were eligible. The treatment consisted of induction (IND) chemotherapy with a fixed dose rate gemcitabine 1,000 mg/m² on days 1 and 8 and CDDP 60 mg/m² on day 1 every 3 weeks for 3 cycles. Subsequently, the patients without progression received CRT of 55.8 Gy/31 fractions with capecitabine 650 mg/m² twice daily. Gemcitabine was given for 3 cycles after CRT. The primary endpoint was time to progression.

Results

Thirty-seven patients with LAPC were enrolled. Median age was 55 years, there were 20 males and 17 females, and ECOG PS was 0 in 6 and 1 in 31. Three patients (9.7 %) achieved partial responses after IND chemotherapy. Twenty-five patients received CRT with a mean radiation dose of 54.0 Gy, with one additional patient achieving a partial response. The median time to progression was 7.2 months (95 % CI, 4.4–10), and the median overall survival was 16.8 months (95 % CI, 12.9–20.7). The grade 3/4 toxicities included neutropenia (29 %/6.5 %), thrombocytopenia (3.2 %/0 %) and anemia (9.7 %/0 %) during the IND phase and grade 3 neutropenia and diarrhea occurring in one and two patients during CRT phase.

Conclusions

IND chemotherapy with gemcitabine and cisplatin followed by CRT with capecitabine and maintenance gemcitabine was well tolerated and exhibited promising efficacy for the treatment of LAPC.

Keywords

Induction chemotherapy Pancreatic cancer Chemoradiotherapy Gemcitabine 

References

  1. 1.
    Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMedCrossRefGoogle Scholar
  3. 3.
    Yeo CJ, Cameron JL, Sohn TA et al (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226:248–257 (discussion 257–260)Google Scholar
  4. 4.
    Cardenes HR, Chiorean EG, Dewitt J et al (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11:612–623PubMedCrossRefGoogle Scholar
  5. 5.
    Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615PubMedCrossRefGoogle Scholar
  6. 6.
    Hawes RH, Xiong Q, Waxman I et al (2000) A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17–31PubMedCrossRefGoogle Scholar
  7. 7.
    Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755CrossRefGoogle Scholar
  8. 8.
    Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  9. 9.
    Klaassen DJ, MacIntyre JM, Catton GE et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378PubMedGoogle Scholar
  10. 10.
    Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRefGoogle Scholar
  11. 11.
    Shibuya K, Oya N, Fujii T et al (2011) Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 34:115–119PubMedGoogle Scholar
  12. 12.
    Sultana A, Tudur Smith C, Cunningham D et al (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96:1183–1190PubMedCrossRefGoogle Scholar
  13. 13.
    Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann Oncol 19:1592–1599PubMedCrossRefGoogle Scholar
  14. 14.
    Saif MW (2008) New developments in the treatment of pancreatic cancer. In: Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30–June 3, 2008. JOP, vol 9, pp 391–397Google Scholar
  15. 15.
    Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCrossRefGoogle Scholar
  16. 16.
    Joensuu TK, Kiviluoto T, Karkkainen P et al (2004) Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60:444–452PubMedCrossRefGoogle Scholar
  17. 17.
    Li CP, Chao Y, Chi KH et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104PubMedCrossRefGoogle Scholar
  18. 18.
    Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56:2563–2568CrossRefGoogle Scholar
  19. 19.
    Mishra G, Butler J, Ho C et al (2005) Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28:345–350PubMedCrossRefGoogle Scholar
  20. 20.
    Marti JL, Hochster HS, Hiotis SP et al (2008) Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 15:3521–3531PubMedCrossRefGoogle Scholar
  21. 21.
    Nakachi K, Furuse J, Kinoshita T et al (2009) A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 66:527–534PubMedCrossRefGoogle Scholar
  22. 22.
    Moureau-Zabotto L, Phelip JM, Afchain P et al (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 26:1080–1085PubMedCrossRefGoogle Scholar
  23. 23.
    Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRefGoogle Scholar
  24. 24.
    Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785PubMedCrossRefGoogle Scholar
  25. 25.
    Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498PubMedGoogle Scholar
  26. 26.
    Demols A, Peeters M, Polus M et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481–485PubMedCrossRefGoogle Scholar
  27. 27.
    Ko AH, Dito E, Schillinger B et al (2006) Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24:379–385PubMedCrossRefGoogle Scholar
  28. 28.
    Huguet F, Andre T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331PubMedCrossRefGoogle Scholar
  29. 29.
    Cengiz M, Zorlu F, Yalcin S et al (2007) Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol 24:239–243PubMedCrossRefGoogle Scholar
  30. 30.
    Crane CH, Janjan NA, Evans DB et al (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29:9–18PubMedCrossRefGoogle Scholar
  31. 31.
    Wolff RA, Evans DB, Gravel DM et al (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246–2253PubMedGoogle Scholar
  32. 32.
    Wilkowski R, Boeck S, Ostermaier S et al (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer–a multi-centre randomised phase II study. Br J Cancer 101:1853–1859PubMedCrossRefGoogle Scholar
  33. 33.
    Wilkowski R, Thoma M, Bruns C et al (2006) Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 7:349–360PubMedGoogle Scholar
  34. 34.
    Mishra G, Butler J, Ho C et al (2005) Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28:345–350PubMedCrossRefGoogle Scholar
  35. 35.
    Schneider BJ, Ben-Joref E, McGinn CJ et al (2005) Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:1325–1330PubMedCrossRefGoogle Scholar
  36. 36.
    Reni M, Cereda S, Balzano G et al (2009) Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 64:1253–1259PubMedCrossRefGoogle Scholar
  37. 37.
    Haddock MG, Swaminathan R, Foster NR et al (2007) Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 25:2567–2572PubMedCrossRefGoogle Scholar
  38. 38.
    Ko AH, Quivey JM, Venook AP et al (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68:809–816PubMedCrossRefGoogle Scholar
  39. 39.
    Landry J, Catalano PJ, Staley C et al (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587–592PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jae-Sung Kim
    • 5
  • Joo Han Lim
    • 2
  • Jee Hyun Kim
    • 3
  • Seock-Ah Im
    • 1
  • Eui Kyu Chie
    • 4
  • Jin-Hyeok Hwang
    • 3
  • Tae-You Kim
    • 1
  • Yung-Jue Bang
    • 1
  • Sung Whan Ha
    • 4
  • Yong Bum Yoon
    • 1
  1. 1.Department of Internal MedicineSeoul National University HospitalSeoulKorea
  2. 2.Department of Internal MedicineInha University HospitalIncheonKorea
  3. 3.Department of Internal MedicineSeoul National University Bundang HospitalSeongnamKorea
  4. 4.Department of Radiation OncologySeoul National University HospitalSeoulKorea
  5. 5.Department of Radiation OncologySeoul National University Bundang HospitalSeongnamKorea

Personalised recommendations